Skip to content
Study details
Enrolling now

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

University of Michigan Rogel Cancer Center
NCT IDNCT07158021ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

75

Study length

about 2 years

Ages

18+

Sex

Female only

Locations

1 site in MI

What this study is about

This trial is testing whether leuprolide or goserelin can help lower estrogen production from the ovaries in women with breast cancer who are pre- or peri-menopausal. Estrogen can fuel the growth of some breast cancer cells. It compares different doses of leuprolide and goserelin to see which one best suppresses ovarian function and reduces estrogen levels.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Electronic Health Record Review
  • 2.Questionnaire Administration
  • 3.Take Goserelin
  • +2 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

goserelin, leuprorelin (GnRH agonist; suppresses testosterone (and estrogen) production after initial surge)

Endpoints

Secondary: Change in FACT-ES Endocrine Symptom Subscale, Incidence of adverse events (AEs)

Procedures

diagnostic